Article and Video CATEGORIES
Assistant Professor of Medicine, Hospital of the University of Pennsylvania, and the Veteran’s Administration Medical Center
What Have We Learned About Debio 1143 (Xevinapant) in Combination with Chemoradiation Therapy for Patients With HNSCC
We are pleased to present this newest video series of updates from ASCO and ESMO 2020, with discussions on updates to head and neck cancer treatments and trials.
Dr. Joshua Bauml, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and Dr. Jared Weiss, Associate Professor of Medicine at UNC Chapel Hill and Vice President of the Board of GRACE chaired this program.
Drs. Bauml and Weiss spoke with Dr. Kathryn Gold, Medical Oncologist and Associate Professor of Medicine at the University of California San Diego and Dr. Ranee Mehra, Professor of Medical Oncology at the University of Maryland, on the newest updates to 2020 trials and studies presented at ASCO and ESMO this year.
For this discussion, Drs. Bauml, Weiss, Gold and Mehra discuss what we have learned about Debio 1143 (Xevinapant) in combination with chemoradiation therapy for patients With HNSCC.
We thank Varian for their support of this program!
To join the conversation, visit https://cancergrace.org/forum.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi amitchouhan,
Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...
I was searching for this, Thank you so much for the info.